BR0102604B1 - composição farmacêutica compreendendo sal monossódico da n-[o- (p-pivaloiloxibenzenossulfonilamino) benzoil] glicina tetrahidratado e uso da mesma. - Google Patents

composição farmacêutica compreendendo sal monossódico da n-[o- (p-pivaloiloxibenzenossulfonilamino) benzoil] glicina tetrahidratado e uso da mesma.

Info

Publication number
BR0102604B1
BR0102604B1 BRPI0102604-6A BR0102604A BR0102604B1 BR 0102604 B1 BR0102604 B1 BR 0102604B1 BR 0102604 A BR0102604 A BR 0102604A BR 0102604 B1 BR0102604 B1 BR 0102604B1
Authority
BR
Brazil
Prior art keywords
pivaloyloxybenzenesulfonylamino
tetrahydrate
benzoyl
glycine
monosodium salt
Prior art date
Application number
BRPI0102604-6A
Other languages
English (en)
Other versions
BR0102604A (pt
Inventor
Akira Takada
Masao Sudoh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0102604A publication Critical patent/BR0102604A/pt
Publication of BR0102604B1 publication Critical patent/BR0102604B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI0102604-6A 2000-06-29 2001-06-28 composição farmacêutica compreendendo sal monossódico da n-[o- (p-pivaloiloxibenzenossulfonilamino) benzoil] glicina tetrahidratado e uso da mesma. BR0102604B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000195853 2000-06-29
JP2000195852 2000-06-29

Publications (2)

Publication Number Publication Date
BR0102604A BR0102604A (pt) 2002-02-13
BR0102604B1 true BR0102604B1 (pt) 2012-06-26

Family

ID=26594951

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0102604-6A BR0102604B1 (pt) 2000-06-29 2001-06-28 composição farmacêutica compreendendo sal monossódico da n-[o- (p-pivaloiloxibenzenossulfonilamino) benzoil] glicina tetrahidratado e uso da mesma.

Country Status (19)

Country Link
US (1) US6552082B2 (pt)
EP (1) EP1166773B1 (pt)
KR (1) KR100725076B1 (pt)
CN (1) CN1263736C (pt)
AT (1) ATE259218T1 (pt)
AU (1) AU782838B2 (pt)
BR (1) BR0102604B1 (pt)
CA (1) CA2351273C (pt)
DE (1) DE60101979T2 (pt)
DK (1) DK1166773T3 (pt)
ES (1) ES2215856T3 (pt)
HU (1) HUP0102699A2 (pt)
MX (1) MXPA01006698A (pt)
NO (1) NO330296B1 (pt)
NZ (1) NZ512486A (pt)
PT (1) PT1166773E (pt)
RU (1) RU2272623C2 (pt)
TR (1) TR200400585T4 (pt)
TW (1) TWI246925B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416600A1 (en) * 2000-07-24 2003-01-20 Ono Pharmaceutical Co., Ltd. Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof
US20050101633A1 (en) * 2001-05-17 2005-05-12 Takeharu Tonai Remedial agent for myelopathic disease
TW200519080A (en) * 2003-10-03 2005-06-16 Ono Pharmaceutical Co Agent containinf (2R)-2-propyloctanic acid as effective component
CA2707484C (en) 2007-12-04 2021-08-10 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
KR101247137B1 (ko) * 2011-03-23 2013-04-01 주식회사 엠씨켐 N-[o-(p-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법
KR101366706B1 (ko) 2012-12-06 2014-02-24 상명대학교서울산학협력단 N-[o-(p-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법
CN104107172B (zh) * 2013-04-18 2017-11-28 上海汇伦生命科技有限公司 西维来司钠注射用冻干粉的制备方法
CN114681435A (zh) * 2020-12-31 2022-07-01 上海汇伦生物科技有限公司 吸入用药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0320253A (ja) 1988-06-13 1991-01-29 Ono Pharmaceut Co Ltd ピバル酸 p―置換フェニルエステル誘導体、それらの製造方法およびそれらを有効成分として含有するエラスターゼ阻害剤
CA1340191C (en) 1988-06-13 1998-12-15 Katsuhiro Imaki Derivatives of p-substituted phenyl ester of pivalic acid
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.
JP3020253B2 (ja) 1990-05-02 2000-03-15 松下電工株式会社 配線器具の取付枠への取付構造
EP0539223A1 (en) 1991-10-25 1993-04-28 Ono Pharmaceutical Co., Ltd. Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase
JPH05194366A (ja) 1991-10-25 1993-08-03 Ono Pharmaceut Co Ltd グリシン誘導体・モノナトリウム塩・4水和物、その製造方法、それを含有する薬剤および該誘導体の中間体の製造方法
JP3193597B2 (ja) 1995-07-28 2001-07-30 小野薬品工業株式会社 グリシン誘導体の製造方法
AU5528299A (en) 1998-09-15 2000-04-03 Naeja Pharmaceutical Inc. Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s)
AU6870800A (en) * 1999-09-06 2001-04-10 Ono Pharmaceutical Co. Ltd. Preventive and therapeutic agents for eye diseases

Also Published As

Publication number Publication date
KR100725076B1 (ko) 2007-06-08
RU2272623C2 (ru) 2006-03-27
NO20013223D0 (no) 2001-06-27
ES2215856T3 (es) 2004-10-16
DE60101979D1 (de) 2004-03-18
NO20013223L (no) 2001-12-31
AU782838B2 (en) 2005-09-01
NZ512486A (en) 2001-12-21
KR20020002242A (ko) 2002-01-09
US20020022738A1 (en) 2002-02-21
BR0102604A (pt) 2002-02-13
CA2351273A1 (en) 2001-12-29
TR200400585T4 (tr) 2004-04-21
CN1263736C (zh) 2006-07-12
CN1341591A (zh) 2002-03-27
DE60101979T2 (de) 2005-01-05
AU5409201A (en) 2002-03-28
CA2351273C (en) 2010-09-07
MXPA01006698A (es) 2004-07-30
US6552082B2 (en) 2003-04-22
HU0102699D0 (en) 2001-08-28
PT1166773E (pt) 2004-05-31
NO330296B1 (no) 2011-03-21
TWI246925B (en) 2006-01-11
DK1166773T3 (da) 2004-06-07
ATE259218T1 (de) 2004-02-15
EP1166773A1 (en) 2002-01-02
HUP0102699A2 (en) 2002-06-29
EP1166773B1 (en) 2004-02-11

Similar Documents

Publication Publication Date Title
DE60141815D1 (de) Reagentien zur bestimmung des aktiven sauerstoffs
MXPA03011522A (es) Derivados de naftil indol sustiduidos como inhibidores del tipo 1 del inhibidor del activador del plasmingeno.
CY1107506T1 (el) Μεθοδος για σταθεροποιηση ενωσεων βενζιμιδαζολης
EP1306375A4 (en) SALTS OF BENZIMIDAZOLE DERIVATIVES AND THEIR USE
EP1018514A4 (en) NF- $ g (k) B INHIBITORS CONTAINING INDANE DERIVATIVES AS ACTIVE INGREDIENT
BR0102604B1 (pt) composição farmacêutica compreendendo sal monossódico da n-[o- (p-pivaloiloxibenzenossulfonilamino) benzoil] glicina tetrahidratado e uso da mesma.
PT976748E (pt) Derivados de pirrolidina com actividade inibidora de fosfolipase a2
PT848004E (pt) Derivados pirrolidina tendo actividade inibidora da fosfolipase a2
HK1048474A1 (en) Substituted thiene-3-yl-sulfonyl amino(thio)carbonyl-triazolin(thi)ones.
DK1043327T3 (da) Phosphonocephem-derivater, fremgangsmåde til fremstilling af disse og anvendelse deraf
ES2180799T3 (es) Tetrahidroquinolinas como antagonistas de nmda (n-metil-d-aspartato).
FI943508A (fi) Pyridiinikarboksimidamidiyhdisteet ja niiden käyttö
ID24846A (id) Turunan-turunan bifenilamidina
MY123191A (en) Concentrated, aqueous herbicidal compositions containing an imidazolinyl acid salt and a glyphosate salt
PT1301477E (pt) Processo para a preparacao de 2,2'-ditiobis (etanossulfonato) dissodico
BR9812982A (pt) Agente anti-reumático
BR9708280A (pt) Compostos de inclusão de diclofenaco/gama-cd
EP0995756A3 (de) Mechanismus-orientierte inhibitoren der Dipeptidylpeptidase I
BR9902096A (pt) Pitazóis.
HUP0002109A2 (hu) (E)-4,6-diklór-3-(2-oxo-1-fenilpirrolidin-3-ilidén-metil)-1H-indol-2-karbonsav kristályos hidratált nátriumsója, eljárás előállítására és az ilyen vegyületet tartalmazó gyógyszerkészítmény
ES2166031T3 (es) Nuevos inhibidores de beta-glucuronidasa.
NO20000054D0 (no) Polyhydroksyalkylpyrazinderivater, deres fremstilling og medisiner inneholdende forbindelsene
AR022364A1 (es) Proceso para la preparacion de n-(fosfonometil)glicina por oxidacion de n-(fosfonometil)glicina n-sustituida y un proceso para la preparacion de unamonoetanolamina n-sustituida
DE69815347D1 (de) Tetrahydrofuranderivate
SE8204641L (sv) Aminosyraderivat

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/22, A61K 9/19, A61K 47/02, A61K 9/08, A61P11/00

Ipc: A61K 31/22 (2010.01), A61K 9/19 (2010.01), A61K 47

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/06/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 12A, 13A E 14A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.